Skip to main content
Log in

Variability in the pharmacokinetics of cyclophosphamide, methotrexate and 5-fluorouracil in women receiving adjuvant treatment for breast cancer

  • Original Articles
  • Methotrexate, 5-Fluorouracil, Cylophosphamide, Variability, Pharmacokinetics, Breast Cancer
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

A total of 23 women with stage II breast cancer receiving adjuvant cyclophosphamide, methotrexate and 5-fluorouracil had detailed pharmacokinetic monitoring performed on the first and third courses of therapy. The area under the concentration time curve (AUC) of each of these three drugs varied by a factor of 3–4 among patients. No systematic change in pharmacokinetics between the first and third courses was seen for cyclophosphamide, methotrexate or 5-fluorouracil, and the mean AUC for each of the three drugs did not change. However, significant intrapatient variability in drug pharmacokinetics was observed for all three drugs such that the AUC, clearance and half-life in an individual on the third course could not be reliably predicted from data generated on the first course. On the basis of these results, cyclophosphamide, methotrexate, and 5-fluorouracil pharmacokinetic data from one treatment would not be useful information from which the doses for subsequent courses could be determined.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bonadonna G, Valagussa P (1981) Dose response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304: 10

    Google Scholar 

  2. Bonadonna G (1989) Conceptual and practical advances in the management of breast cancer. J Clin Oncol 7: 1380

    Google Scholar 

  3. Burkputt AR, Boyd MR (1980) Measurement of 5-fluorouracil in plasma by HPLC. Ann Biochem 106: 432

    Google Scholar 

  4. D'Argenio DZ, Schumitsky A (1979) A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Methods Programs Biomed 9: 115

    Google Scholar 

  5. Diasio RB, Harris BE (1989) Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16: 215

    Google Scholar 

  6. Egorin MJ, Forrest A, Belani CP, Ratain MJ, Abrams JS, Van Echo DA (1989) A limited sampling strategy for cyclophosphamide pharmacokinetics. Cancer Res 49: 3129

    Google Scholar 

  7. Egorin MJ, Van Echo DA, Olman EA, Whitacre MY, Forrest A, Aisner J (1985) Prospective validation of a pharmacologically based dosing scheme for the cisplatin analogue diamminecyclo-butanedicarboxylatoplatinum. Cancer Res 45: 6502

    Google Scholar 

  8. Gibaldi M, Perrier D (1982) Pharmacokinetics. Marcel Dekker, New York

    Google Scholar 

  9. Hardy RW, Erlichman C, Soldin SJ (1984) High-performance liquid chromatographic measurement of cyclophosphamide in plasma. Ther Drug Monit 6:313

    Google Scholar 

  10. Henderson IC, Hayes DF, Gelman R (1988) Dose response in the treatment of breast cancer: a critical review. J Clin Oncol 6: 1501

    Google Scholar 

  11. Hryniuk W, Levine L (1986) Dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 4: 1162

    Google Scholar 

  12. Jolivet J, Cowan KH, Curt GA, Clendeninn NJ, Chabner BA (1983) The pharmacology and clinical use of methotrexate. N Engl J Med 309: 1094

    Google Scholar 

  13. Kerr IG, Jolivet J, Collins JM, Drake JC, Chabner BA (1983) Test dose for predicting high dose methotrexate infusions. Clin Pharmacol Ther 33: 44

    Google Scholar 

  14. Milano G, Roman P, Ishter R, Prenay M, Renee N, Namer M (1988) Dose versus pharmacokinetics for predicting tolerance to 5 day cotinuous infusion of 5-fluorouracil. Int J Cancer 41: 537

    Google Scholar 

  15. Moore M (1991) Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 20: 194

    Google Scholar 

  16. Moore MJ, Erlichman C (1987) Therapeutic drug monitoring in oncology. Clin Pharmacokinet 13: 205

    Google Scholar 

  17. Slee PH, DeBruijn EA, Dreissen OM, Oosterom AT van (1983) Pharmacokinetics of the cytostatic drugs used in the CMF regimen. Anticancer Res 3: 269

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

This research was supported by the National Cancer Institute of Canada

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moore, M.J., Erlichman, C., Thiessen, J.J. et al. Variability in the pharmacokinetics of cyclophosphamide, methotrexate and 5-fluorouracil in women receiving adjuvant treatment for breast cancer. Cancer Chemother. Pharmacol. 33, 472–476 (1994). https://doi.org/10.1007/BF00686503

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00686503

Keywords

Navigation